Implementing preclinical study findings to protocol design: Translational studies with alloreactive CTL for gliomas

American Journal of Translational Research

Volumn 4, Issue 1, 2012, Pages 114-126

  Hickey, Michelle J ^a   Malone, Colin C ^a   Erickson, Kate E ^a   Gomez, German G ^c   Young, Emma L ^a   Liau, Linda M ^a,b   Prins, Robert M ^a,b   Kruse, Carol A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

Author keywords

Adoptive immunotherapy; Astrocytoma; Bevacizumab; Cellular therapy; CTL; Glioma; Immunotherapy; Temozolomide

Indexed keywords

BEVACIZUMAB; GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2; TEMOZOLOMIDE;

ADOPTIVE TRANSFER; ALLOREACTIVE CYTOTOXIC T LYMPHOCYTE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL VIABILITY; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; COST CONTROL; CULTURE MEDIUM; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GLIOMA; HUMAN; HUMAN CELL; LYMPHOCYTOTOXICITY; PHENOTYPE; PILOT STUDY; PRECLINICAL STUDY; QUALITY CONTROL; RADIATION DOSE; RECURRENT DISEASE; STUDY DESIGN; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TISSUE CULTURE; TRANSLATIONAL RESEARCH; UPREGULATION;

EID: 84856612705     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. CBTRUS Statistical report: Primary brain and central nervous system tumors diagnosed in the United States, 2004-2006, Central Brain Tumor Registry of the United States. CBTRUS 2010; p1-61.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG and Mirimanoff RO. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
4. Hickey MJ, Malone CC, Erickson KL, Jadus MR, Prins RM, Liau LM and Kruse CA. Cellular and vaccine therapeutic approaches for gliomas. J Transl Med 2010; 8: 100-110.
5. Fleshner M, Watkins LR, Redd JM, Kruse CA and Bellgrau D. A 9L gliosarcoma transplantation model for studying adoptive immunotherapy into the brains of conscious rats. Cell Transplant. 1992; 1: 307-312.
6. Kruse CA, Kong Q, Schiltz PM and Kleinschmidt-DeMasters BK. Migration of activated lymphocytes when adoptively transferred into cannulated rat brain. J Neuroimmunol 1994; 55: 11-21.
7. Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-DeMasters B and Bellgrau D. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. Proc Natl Acad Sci USA 1990; 87: 9577-9581.
8. Kruse CA, Schiltz PM, Bellgrau D, Kong Q and Kleinschmidt-DeMasters BK. Intracranial ad ministrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors. J Neurooncol 1994; 19: 161-168.
9. Redd JM, Lagarde AC, Kruse CA and Bellgrau D. Allogeneic tumor-specific cytotoxic T lymphocytes. Cancer Immunol Immunother 1992; 34: 349-354.
10. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J and Lillehei KO. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 1997; 45: 77-87.
11. Kruse CA and Rubinstein D. Cytotoxic T Lymphocytes Reactive to Patient Major Histocompatibility Proteins for Therapy of Recurrent Primary Brain Tumors. In: Liau LM, Cloughesy TF, Becker DP, Bigner DD, editors. Brain Tumor Immunotherapy. Totowa: Humana Press; 2001. p. 149-170.
12. Kruse CA and Beck LT. Artificial-capillarysystem development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours. Biotechnol Appl Biochem 1997; 25 (Pt 3): 197-205.
13. Lampson LA. Interpreting MHC class I expression and class I/class II reciprocity in the CNS: reconciling divergent findings. Microsc Res Tech 1995; 32: 267-285.
14. Lampson LA and Hickey WF. Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from histologically normal to that showing different levels of glial tumor involvement. J Immunol 1986; 136: 4054-4062.
15. Read SB, Kulprathipanja NV, Gomez GG, Paul DB, Winston KR, Robbins JM and Kruse CA. Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-γ or IFN- γ gene modification. J Interferon Cytokine Res 2003; 23: 379-393.
16. Kuppner MC, Hamou MF and de Tribolet N. Activation and adhesion molecule expression on lymphoid infiltrates in human glioblastomas. J Neuroimmunol 1990; 29: 229-238.
17. Bigner DD, Bigner SH, Ponten J, Westermark B, Mahaley MS, Ruoslahti E, Herschman H, Eng LF and Wikstrand CJ. Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 1981; 40: 201-229.
18. Kulprathipanja NV and Kruse CA. Microglia phagocytose alloreactive CTL-damaged 9L gliosarcoma cells. J Neuroimmunol 2004; 153: 76-82.
19. Cohen MH, Shen YL, Keegan P and Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009; 14: 1131-1138.
20. Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J and Lejeune F. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol 1998; 42: 433-440.
21. Gomez GG and Kruse CA. Isolation and culture of human brain tumor cells. Methods Mol Med 2004; 88: 101-109.
22. Gomez GG, Varella-Garcia M and Kruse CA. Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization. Cancer Genet Cytogenet 2006; 165: 121-134.
23. Gomez GG, Hickey MJ, Tritz R and Kruse CA. Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: Downregulation of multiple proapoptotic factors. Gene Ther Mol Biol 2008; 12: 101-110.
24. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H and Jadus MR. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cellbased therapeutics. Clin Cancer Res 2007; 13: 566-575.
25. Gomez GG, Read SB, Gerschenson LE, Santoli D, Zweifach A and Kruse CA. Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors. Neuro Oncol 2004; 6: 83-95.
26. Dillman RO, Duma CM, Schiltz PM, DePriest C, Ellis RA, Okamoto K, Beutel LD, De Leon C and Chico S. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 2004; 27: 398-404.
27. Yannelli JR, Thurman GB, Dickerson SG, Mrowca A, Sharp E and Oldham RK. An improved method for the generation of human lymphokine activated killer cells. J Immunol Methods 1987; 100: 137-145.
28. Topalian SL, Muul LM, Solomon D and Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 1987; 102: 127-141.
29. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH and Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729.
30. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M and Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
31. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS and Fine HA. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740-745.
32. Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler JP, Muro K, Dubner S, Rademaker AW, Renfrow J and Bredel M. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010; 116: 5297-5305.
33. Gomez GG and Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol 2006; 10: 133-146.
34. Yang I HN, Smith ZA, Han SJ, Parsa AT. Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy. Neurosurg Clin N Am. 2010; 21: 181-186.
35. Floeth FW, Wittsack HJ, Engelbrecht V and Weber F. Comparative follow-up of enhancement phenomena with MRI and proton MR spectroscopic imaging after intralesional immunotherapy in glioblastoma--Report of two exceptional cases. Zentralbl Neurochir 2002; 63: 23-28.
36. Sakaguchi S, Takahashi T, Yamazaki S, Kuniyasu Y, Itoh M, Sakaguchi N and Shimizu J. Immunologic self tolerance maintained by Tcell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity. Microbes Infect 2001; 3: 911-918.
37. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, Williams L, Foster T, Sepkowitz KA and Chapman PB. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004; 22: 610-616.
38. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC and Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213.
39. Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, Hurwitz HI, Dev I, Nixon AB, Lyerly HK, Clay T and Morse MA. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008; 57: 1115-1124.
40. Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD and Jooss K. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006; 12: 6808-6816.
41. Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, Hicklin DJ, Jaffee EM and Emens LA. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 2007; 13: 3951-3959.
42. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA and Stupp R. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004; 10: 3728-3736.
43. Desjardins A, Reardon DA, Herndon JE, 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS and Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008; 14: 7068-7073.
44. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD and Heimberger AB. Greater chemotherapyinduced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIIIexpressing tumor cells in patients with glioblastoma. Neuro Oncol 2011; 13: 324-333.